<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00354939</url>
  </required_header>
  <id_info>
    <org_study_id>HOE901_4049</org_study_id>
    <nct_id>NCT00354939</nct_id>
  </id_info>
  <brief_title>Insulin Analogue With Continuous Glucose Monitoring System (CGMS) Measurement</brief_title>
  <acronym>SAFIR</acronym>
  <official_title>10-week, Open, National, Multicenter Clinical Trial to Evaluate the Safety of Insulin Glargine in Type 2 Diabetes Mellitus Patients, on Intensified Conventional Therapy (ICT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary objective:&#xD;
&#xD;
      Difference in frequency of subjects with conventionally detected hypoglycemia by the subject&#xD;
      [at least one measurement smaller/equal 60mg/dl documented in the 8-point profile in the case&#xD;
      record form (CRF) or documentation of symptomatic hypoglycemia in the CRF through Visits 8/9]&#xD;
      compared to CGMS detected blood glucose values smaller/equal 60mg/dl during CGMS measurements&#xD;
      (at least one measurement through Visits 8/9) after eight weeks of treatment with insulin&#xD;
      glargine.&#xD;
&#xD;
      Secondary objective:&#xD;
&#xD;
      Secondary study objectives were to investigate the safety and efficacy of a treatment change&#xD;
      to insulin glargine in ICT treated subjects in terms of:&#xD;
&#xD;
        -  Percentage of blood glucose measurements(CGMS data)smaller/equal 60mg/dl [3.3 mmol/l].&#xD;
&#xD;
        -  Percentage of nocturnal blood glucose measurements(CGMS data)smaller/equal 60mg/dl[3.3&#xD;
           mmol/l].&#xD;
&#xD;
        -  Percentage of daytime blood glucose measurements(CGMS data)smaller/equal 60mg/dl[3.3&#xD;
           mmol/l].&#xD;
&#xD;
        -  Area under the curve (AUC smaller/equal 60)and time(t smaller/equal 60)for blood glucose&#xD;
           smaller/equal 60mg/dl[3.3mmol/l], area under the curve (AUC greater/equal 180)and time&#xD;
           (t greater/equal 180) for blood glucose greater/equal 180mg/dl[10.0mmol/l].&#xD;
&#xD;
        -  Area under the curve (AUC smaller/equal 60)and time(t smaller/equal 60)for blood glucose&#xD;
           smaller/equal 60mg/dl[3.3mmol/l]during the day (AUC 06.00am - 10.00pm)and during the&#xD;
           night(AUC 10.00pm - 06.00am).&#xD;
&#xD;
        -  Area under the curve (AUC greater/equal 180)and time(t greater/equal 180)for blood&#xD;
           glucose greater/equal 180mg/dl[10.0mmol/l]during the day (AUC 06.00am - 10.00pm)and&#xD;
           during the night(AUC 10.00pm - 06.00am).&#xD;
&#xD;
        -  Frequency of subjects with nocturnal blood glucose value smaller/equal 60mg/dl[3.3&#xD;
           mmol/l].&#xD;
&#xD;
        -  Frequency of subjects with asymptomatic nocturnal blood glucose smaller/equal&#xD;
           60mg/dl[3.3 mmol/l].&#xD;
&#xD;
        -  Frequency of subjects with symptomatic nocturnal blood glucose smaller/equal 60mg/dl&#xD;
           [3.3 mmol/l].&#xD;
&#xD;
        -  Frequency of subjects with daytime blood glucose smaller/equal 60mg/dl [3.3 mmol/l].&#xD;
&#xD;
        -  Frequency of subjects with asymptomatic daytime blood glucose smaller/equal 60mg/dl[3.3&#xD;
           mmol/l].&#xD;
&#xD;
        -  Frequency of subjects with symptomatic daytime blood glucose smaller/equal 60mg/dl[3.3&#xD;
           mmol/l].&#xD;
&#xD;
        -  Frequency of subjects with hyperglycemic blood glucose(greater/equal&#xD;
           180mg/dl,[10.0mmol/l]).&#xD;
&#xD;
        -  Frequency of subjects with symptomatic hypoglycemia(smaller/equal 60mg/dl [3.3mmol]).&#xD;
&#xD;
        -  Frequency of subjects with severe hypoglycemia(smaller/equal 36mg/dl [2.0mmol/l]).&#xD;
&#xD;
        -  Blood glucose values of 8-point profiles.&#xD;
&#xD;
        -  Mean daytime &amp; mean nocturnal blood glucose of 8-point-profiles.&#xD;
&#xD;
        -  HbA1c.&#xD;
&#xD;
        -  Fasting blood glucose (FBG).&#xD;
&#xD;
        -  Dose of insulin.&#xD;
&#xD;
        -  Adjustment of insulin.&#xD;
&#xD;
        -  Body weight, body mass index.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">March 2004</completion_date>
  <primary_completion_date type="Actual">March 2004</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of subjects with conventionally detected hypoglycemia</measure>
  </primary_outcome>
  <enrollment>480</enrollment>
  <condition>Diabetes Mellitus Type 2</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glargine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with type 2 diabetes mellitus (no history of ketoacidosis)and stable&#xD;
             treatment with NPH insulin(once or twice daily)and mealtime insulin for at least 3&#xD;
             months.&#xD;
&#xD;
          -  HbA1c values smaller/equal 8.0%(measured at screening visit, Visit 1).&#xD;
&#xD;
          -  Ability and willingness to perform continuous and self monitoring blood glucose&#xD;
             profiles, using a self monitoring blood glucose meter as well as carrying the&#xD;
             continuous blood glucose meter at least two times for 72 hours throughout the study at&#xD;
             home.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  All forms of diabetes other than type 2 diabetes mellitus.&#xD;
&#xD;
          -  Oral antidiabetic drugs(OADs)and/or insulins other than NPH and mealtime insulins,&#xD;
             except metformin(stable dose for a minimum of 3 months, no dose adjustments during the&#xD;
             study).&#xD;
&#xD;
          -  Pregnant(as determined by urine pregnancy test at Visit 1)or breast-feeding.&#xD;
&#xD;
          -  Women of childbearing potential who did not take adequate contraceptive protection&#xD;
             such as systemic hormones or who planned to become pregnant during the study.&#xD;
&#xD;
          -  Likelihood of requiring treatment during the study period with drugs not permitted by&#xD;
             the study protocol (e.g. systemic corticosteroids).&#xD;
&#xD;
          -  History of hypersensitivity to the study medication or to drugs with similar chemical&#xD;
             structures.&#xD;
&#xD;
          -  Treatment with any investigational drugs in the last month before study entry.&#xD;
&#xD;
          -  History of drug or alcohol abuse.&#xD;
&#xD;
          -  Diabetic retinopathy with surgical treatment (laser photocoagulation or vitrectomy) in&#xD;
             the 3 months prior to study entry or which required surgical treatment within the&#xD;
             study.&#xD;
&#xD;
          -  Clinically relevant cardiovascular, gastrointestinal, hepatic, neurological,&#xD;
             endocrine, hematological or other major systemic diseases making implementation of the&#xD;
             protocol or interpretation of the study results difficult.&#xD;
&#xD;
          -  Known impaired hepatic or renal function.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Landgraf, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <results_reference>
    <citation>Zick R, Petersen B, Richter M, Haug C; SAFIR Study Group. Comparison of continuous blood glucose measurement with conventional documentation of hypoglycemia in patients with Type 2 diabetes on multiple daily insulin injection therapy. Diabetes Technol Ther. 2007 Dec;9(6):483-92.</citation>
    <PMID>18034602</PMID>
  </results_reference>
  <verification_date>August 2010</verification_date>
  <study_first_submitted>July 19, 2006</study_first_submitted>
  <study_first_submitted_qc>July 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2006</study_first_posted>
  <last_update_submitted>August 30, 2010</last_update_submitted>
  <last_update_submitted_qc>August 30, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2010</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

